A critical overview of animal models of psychiatric disorders: challenges and perspectives.

Animal models of psychiatric disorders are a challenging but highly relevant issue. Most psychiatric disorders are very heterogeneous syndromes, resulting from multiple and varied causal factors and characterized by symptoms that can only be inferred with significant limitations in non-human models. As constructing a model that reproduces a whole psychiatric syndrome seems virtually impossible, researchers have tried to focus on endophenotypes, i.e., discrete traits that are more proximal to predisposing genes than the whole syndrome. These can be explored in a wide range of approaches, such as in pharmacological, lesion, and environmental models. Another challenge is to understand how genes interact with environmental factors over time to result in the syndromic phenotype. A better understanding of the subcellular mechanisms that enhance or allow brain resistance to environmental influences is required, as is a global thesis compatible with the diversity of diseases sharing similar behavioral and biological traits. With an experimental inventory of the possible causes of minor developmental failures, we may systematically explore their consequences in the adult animal and be able to decide if this will enlighten the understanding of one or another psychiatric disease.

[1]  R. Andrew Chambers,et al.  The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia , 2009, Behavioural Brain Research.

[2]  I. Gottesman,et al.  The endophenotype concept in psychiatry: etymology and strategic intentions. , 2003, The American journal of psychiatry.

[3]  S. Sealfon,et al.  Persistent effects of chronic clozapine on the cellular and behavioral responses to LSD in mice , 2012, Psychopharmacology.

[4]  Karl J. Friston,et al.  Dysconnection in Schizophrenia: From Abnormal Synaptic Plasticity to Failures of Self-monitoring , 2009, Schizophrenia bulletin.

[5]  J. Cruces,et al.  Early Maternal Deprivation in Rats , 2009, Annals of the New York Academy of Sciences.

[6]  Kole T. Roybal,et al.  Mania-like behavior induced by disruption of CLOCK , 2007, Proceedings of the National Academy of Sciences.

[7]  H. Jaaro-Peled.  Gene models of schizophrenia: DISC1 mouse models. , 2009, Progress in brain research.

[8]  Ulrich Schall,et al.  Finding the needle in the haystack: A review of microarray gene expression research into schizophrenia , 2012, The Australian and New Zealand journal of psychiatry.

[9]  K. Breen,et al.  Intrauterine inflammation, insufficient to induce parturition, still evokes fetal and neonatal brain injury , 2011, International Journal of Developmental Neuroscience.

[10]  D. Malone,et al.  Current pharmacological models of social withdrawal in rats: relevance to schizophrenia , 2010, Behavioural pharmacology.

[11]  K. Talbot.  The sandy (sdy) mouse: a dysbindin-1 mutant relevant to schizophrenia research. , 2009, Progress in brain research.

[12]  B. Pouzet,et al.  Spatial Memory Deficits Induced by Perinatal Treatment of Rats with PCP and Reversal Effect of D-Serine , 2004, Neuropsychopharmacology.

[13]  G. Juckel,et al.  Dopamine and serotonin levels following prenatal viral infection in mouse—Implications for psychiatric disorders such as schizophrenia and autism , 2008, European Neuropsychopharmacology.

[14]  D. Javitt,et al.  Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. , 2012, Schizophrenia bulletin.

[15]  P. Willner.  Chronic Mild Stress (CMS) Revisited: Consistency and Behavioural-Neurobiological Concordance in the Effects of CMS , 2005, Neuropsychobiology.

[16]  D. Weinberger,et al.  Neonatal Damage of the Ventral Hippocampus Impairs Working Memory in the Rat , 2002, Neuropsychopharmacology.

[17]  N. Swerdlow,et al.  Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. , 2000, Behavioural pharmacology.

[18]  A. Fink-Jensen,et al.  Pharmacological characterization of social isolation-induced hyperactivity , 2011, Psychopharmacology.

[19]  A. Louilot,et al.  Early Prefrontal Functional Blockade in Rats Results in Schizophrenia-Related Anomalies in Behavior and Dopamine , 2012, Neuropsychopharmacology.

[20]  D J Porteous,et al.  Schizophrenia and affective disorders--cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. , 2001, American journal of human genetics.

[21]  S. Hyman,et al.  Animal models of neuropsychiatric disorders , 2010, Nature Neuroscience.

[22]  J. Feldon,et al.  Behavioral animal models of antipsychotic drug actions. , 2012, Handbook of experimental pharmacology.

[23]  João Vinícius Salgado,et al.  Modelos experimentais de esquizofrenia: uma revisão , 2006 .

[24]  J. Moolman-Smook,et al.  Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia , 2011, Psychopharmacology.

[25]  A. Grace,et al.  Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia , 2008, Neurotoxicity Research.

[26]  G. Laviola,et al.  Gene–environment interaction during early development in the heterozygous reeler mouse: Clues for modelling of major neurobehavioral syndromes , 2009, Neuroscience & Biobehavioral Reviews.

[27]  M. Martres,et al.  Functional alterations of nicotinic neurotransmission in dopamine transporter knock-out mice , 2007, Neuropharmacology.

[28]  Karl J. Friston.  The disconnection hypothesis , 1998, Schizophrenia Research.

[29]  G. Sandner,et al.  [Experimental models of schizophrenia--a review]. , 2006, Revista brasileira de psiquiatria.

[30]  S. Dudek,et al.  Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice , 2007, Nature.

[31]  F. Fumagalli,et al.  Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress. , 2012, The international journal of neuropsychopharmacology.

[32]  M. Sarter,et al.  Transient Inactivation of the Neonatal Ventral Hippocampus Impairs Attentional Set-Shifting Behavior: Reversal with an α7 Nicotinic Agonist , 2012, Neuropsychopharmacology.

[33]  D. Stein,et al.  Early maternal separation leads to down-regulation of cytokine gene expression , 2012, Metabolic Brain Disease.

[34]  P. DeRosse,et al.  Molecular Genetics of the Psychosis Phenotype , 2012, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[35]  N. Swerdlow,et al.  Lesion size and amphetamine hyperlocomotion after neonatal ventral hippocampal lesions: more is less , 2001, Brain Research Bulletin.